Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

Inclusion Criteria:Age 18-85 ;Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.Exclusion Criteria:Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;The presence of a contraindication to thrombolytic therapy of ischemic stroke;Pregnancy or lactation.